Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 23:4:263.
doi: 10.3389/fonc.2014.00263. eCollection 2014.

The Biology and Targeting of FLT3 in Pediatric Leukemia

Colleen E Annesley  1 , Patrick Brown  1
Affiliations
Review

The Biology and Targeting of FLT3 in Pediatric Leukemia

Colleen E Annesley et al. Front Oncol. .

Abstract

Despite remarkable improvement in treatment outcomes in pediatric leukemia over the past several decades, the prognosis for high-risk groups of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as for relapsed leukemia, remains poor. Intensification of chemotherapy regimens for those at highest risk has improved success rates, but at the cost of significantly increased morbidity and long-term adverse effects. With the success of imatinib in Philadelphia-chromosome-positive leukemia and all-trans retinoic acid in acute promyelocytic leukemia, the quest to find additional molecularly targeted therapies has generated much excitement over recent years. Another such possible target in pediatric acute leukemia is FMS-like tyrosine kinase 3 (FLT3). FLT3 aberrations are among the most frequently identified transforming events in AML, and have significant clinical implications in both high-risk pediatric AML and in certain high-risk groups of pediatric ALL. Therefore, the successful targeting of FLT3 has tremendous potential to improve outcomes in these subsets of patients. This article will give an overview of the molecular function and signaling of the FLT3 receptor, as well as its pathogenic role in leukemia. We review the discovery of targeting FLT3, discuss currently available FLT3 inhibitors in pediatric leukemia and results of clinical trials to date, and finally, consider the future promise and challenges of FLT3 inhibitor therapy.

Keywords: FLT3; FLT3 inhibitor; MLL; MLLr; tyrosine kinase inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic illustrating the structure and function of FLT3, including the sites of the most common activating mutations.
See this image and copyright information in PMC

References

    1. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol (2012) 30(14):1663–9 10.1200/JCO.2011.37.8018 - DOI - PMC - PubMed
    1. Rubnitz JE. Childhood acute myeloid leukemia. Curr Treat Options Oncol (2008) 9(1):95–105 10.1007/s11864-008-0059-z - DOI - PubMed
    1. Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS. Challenging issues in pediatric oncology. Nat Rev Clin Oncol (2011) 8(9):540–9 10.1038/nrclinonc.2011.95 - DOI - PMC - PubMed
    1. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol (2009) 27(31):5175–81 10.1200/JCO.2008.21.2514 - DOI - PMC - PubMed
    1. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood (2002) 100(13):4298–302 10.1182/blood-2002-02-0632 - DOI - PubMed